There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prelude Therapeutics (PRLD – Research Report) ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its ...

The biotechnology sector is known for its high-risk, high-reward nature, and Prelude faces significant competition from both established pharmaceutical companies and other emerging biotech firms.

Barclays analyst Peter Lawson maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report) yesterday and set a price target of ...

Success in these endeavors could position Prelude as a leader in precision oncology, attracting attention from investors, partners, and larger pharmaceutical companies looking to expand their ...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small ...

Prelude Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and ...

The biotechnology sector is known for its high-risk, high-reward nature, and Prelude faces significant competition from both established pharmaceutical companies and other emerging biotech firms. Many ...